TCA
UTHR icon

Transcend Capital Advisors’s United Therapeutics UTHR Stock Holding History

Transcend Capital Advisors’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-641
Closed -$312K – 779
2025
Q4 		$312K Buy
+641
New +$299K 0.02% 514

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Transcend Capital Advisors's UTHR Position: Q1 2026 in Review

Transcend Capital Advisors sold out of United Therapeutics (UTHR) in Q1 2026, closing a stake of 641 shares — an estimated $312K sold.

Transcend Capital Advisors first reported a position in UTHR in Q4 2025 and held it in 1 quarter. The position peaked at $312K in Q4 2025. 854 funds tracked by Wall St. Rank hold UTHR as of Q1 2026.

  • Transcend Capital Advisors reported no remaining United Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Transcend Capital Advisors sold 641 United Therapeutics shares in Q1 2026, an estimated $312K.
  • Transcend Capital Advisors first reported a position in United Therapeutics in Q4 2025 and held it in 1 quarter.
  • Transcend Capital Advisors's United Therapeutics position peaked at $312K in Q4 2025.
  • 854 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2026.

Based on Transcend Capital Advisors's 13F filing for Q1 2026, filed 13 May 2026.